We believe in Transparency

We believe pharma and device companies make a huge difference in human lives. We believe patient/physician relationship should be based on 100% trust. Therefore, We believe and support global transparency movement. Our solutions make compliance with transparency and other regulations a welcome breeze.

COMPLIANCE INSIGHTS

View, monitor and analyze all your compliance data in one place.

HCP ENGAGE

Multichannel solution to better manage consent, disputes and pre-disclosure review.

MARKET VISION

Market and competitor intelligence at your fingertips.

YOUR INSURANCE AGAINST BIG PHARMA SCANDAL

What spend are you going to report under Sunshine Payments or EFPIA? Do you know what is in your data?

What will a journalist conclude when they access your public spend records? What will the OIG find as they look for co-relation in spend and Med Part D data under their 2017 work plan?

Let qordata Compliance Insights give you visibility into your own spend. It’s the kind of visibility the CMS/DOJ world wish for.

LEARN MORE

qorcommunity

The latest Pharmaceutical Compliance, Transparency and Analytics insights from around the world, now at your fingertips. Get expert solutions to your specific Pharma Spend Issues.

SIGN UP AS AN EXPERT

Seth Whitelaw

Founder of Whitelaw Compliance Group, LLC

Thomas Sullivan

President of Rockpointe

Kristin Buske

Head MSL Excellence at Merck

Elisabeth Kohoutek

Associate at King & Spalding

Maite Vazquez Calo

Legal Expert on Data Privacy

Brian A Dahl

Principal at Dahl Compliance Consulting LLC

Case Study

Efficiency and Foresight: The qordata Advantage For Zimmer Biomet

For Zimmer Biomet, Compliance Insights, a dedicated CMS Open Payments Solution, was an affirmative response to both. Within a short period, Zimmer Biomet recorded 50% cost reduction, and a corresponding error rate reduction. It achieved quantifiable savings in time, efficiency, and gained better insights.

DOWNLOAD

Trusted by great companies

Helping thousands of people and companies communicate and work better.

OUR SOLUTIONS CAN SIMPLIFY YOUR COMPLIANCE EFFORTS.

UPCOMING EVENT

11th Annual Forum on Transparency & Aggregate Spend
14 Aug to 16 Aug, 2017
8:00 am to 6:00 pm EST
The Ritz-Carlton, Washington, DC, United States
VIEW ALL EVENTS

UPCOMING WEBINAR

No Upcoming Webinar
No Upcoming Webinar
No Upcoming Webinar
VIEW ALL WEBINARS

Press Release

qordata Releases Open Payments Data 2016

Princeton, New Jersey: qordata has released Open Payments Data 2016 less than 24 hours after the publication of 11.96 million financial transactions, (US $ value 8.18 billion) on the CMS Website.

READ FULL STORY

Recent Blog Posts

Thought Leadership —Transparency, Insights And Disclosure

When It Comes To CMS Reporting, Context Is Key
Ned Mumtaz
Written By Ned Mumtaz

Regulator visitors to this blog will know how important it is for qordata to get facts about pharmaceutical spend data right. We would go so far as to say that protecting the sanctity, validity and relevance of this data has a sacred status with us. But before data can be all this, it needs to undergo a number of internal and external processes. Unlike many of the technically-sophisticated and complex processes needed for onward submission, one of the most basic, and most critical requires neither. That process is: Giving data the right context. In a webinar-cum-discussion I hosted last month, I asked my panelists about some of the challenges they face in their organizations’ compliance programs. All three panelists Elizabeth […]

Seven Instant Insights From CMS Open Payments Data 2016: Part II
Jeanine Sieja
Written By Jeanine Sieja

In our last blog, we described spend differences in Grant payments and alluded to how drug launch and approval could have contributed to this. This blog takes a more in-depth take on how spend by drug has changed in 2016. Insight #4 Say Yes To Drugs (But Only Some Of Them) This year, when qordata’s data team listed the top ten drugs that drew the most spend, we observed that a full 50% belonged to oncology. That’s right. Spending on cancer treatment registered most spending from pharmaceutical companies across the United States. Questions arising from this are: How did YoY spend-by-drug patterns change within this category? In the five months that data was collected in 2013, the proportion of oncology […]

Seven Instant Insights From CMS Open Payments Data 2016
George Gaffey
Written By George Gaffey

People seeking spend data on a specific physician will be searching through more than 600,000 physicians and/or going through 1,100 teaching hospital records with the latest update CMS makes in its Open Payments  Database. At qordata, we have employed our data engineering chops to make your life just that much easier. This is the second of a three-part series describing seven instant insights from the CMS Open Payments Data Release 2016*. How have medical device and drug manufacturers’ spend patterns changed in each since the introduction of the Sunshine Payments Act? How many ways can a medical drug/device manufacturer make a transfer of value (ToV) to a physician or teaching hospital? Seventeen. You might be familiar with R&D, Consulting Fees […]

OUR SOLUTIONS CAN SIMPLIFY YOUR COMPLIANCE EFFORTS.